Evidence map›Paper›PMID 25894689›Full record

ArticleCell cycle (Georgetown, Tex.)2015

Bisphosphonates: from softening water to treating PXE.

Stephanie N Moore, S Bobo Tanner, Jonathan G Schoenecker

Registry-linked trialAbstract readNewsComment
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04660461 (Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04660461 phase4unknown statusnot on this mapstarted 2020, after this paper: background citation

Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)

TypeinterventionalSponsorFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludRan2020 to 2021Enrolled20ConditionsGrönblad-Stranberg Disease (Pseudoxanthoma Elasticum)ArmsLansoprazole 30mg, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Determining the pharmacologic window of bisphosphonates that mitigates severe injury-induced osteoporosis and muscle calcification, while preserving fracture repair.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Stephanie N Moorea Department of Orthopaedics ; Vanderbilt University Medical Center ; Nashville , TN USA.
S Bobo Tanner
Jonathan G Schoenecker

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AlendronateAnimalsATP-Binding Cassette TransportersBone Density Conservation AgentsEtidronic AcidFemaleHumansMalePseudoxanthoma ElasticumVascular CalcificationAlendronateATP-Binding Cassette TransportersBone Density Conservation AgentsEtidronic AcidABCC6anti-mineralizationBisphosphonatecalcificationENPP1GACIPXEpyrophosphate

Identifiers

PMID25894689
PMCPMC4614008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.